Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -164.08M | -120.74M | -122.27M | -133.04M | -118.96M |
| Total Depreciation and Amortization | 1.03M | 1.17M | 1.97M | 3.21M | 4.39M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.45M | -44.78M | -50.44M | -47.32M | -54.90M |
| Change in Net Operating Assets | -37.02M | -25.40M | -14.17M | 274.00K | -6.24M |
| Cash from Operations | -208.51M | -189.74M | -184.91M | -176.87M | -175.71M |
| Capital Expenditure | -868.00K | -612.00K | -1.16M | -1.31M | -1.47M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -329.00K | 59.26M | 200.80M | 168.31M | 144.04M |
| Cash from Investing | -1.20M | 58.65M | 199.63M | 167.00M | 142.57M |
| Total Debt Issued | 180.85M | 142.59M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 866.00K | 539.00K | 314.00K | 122.00K | 118.00K |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -3.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.15M | -1.15M | 0.00 | 0.00 | 45.00M |
| Cash from Financing | 180.57M | 141.98M | 314.00K | 122.00K | 42.12M |
| Foreign Exchange rate Adjustments | 6.00K | 39.00K | 10.00K | 3.00K | -4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.14M | 10.92M | 15.05M | -9.75M | 8.98M |